Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| Profile Name | ERBB2 Y772_A775dup |
| Gene Variant Detail | |
| Relevant Treatment Approaches | HER inhibitor (Pan) HER2 Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER2 Inhibitor | Sapitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Sapitinib (AZD8931) in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER2 Inhibitor | Sapitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM) demonstrated resistance to Sapitinib (AZD8931) treatment in culture (PMID: 29967253). | 29967253 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | predicted - sensitive | Luminespib | Preclinical - Cell culture | Actionable | In a preclinical study, Luminespib (AUY922) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) in culture (PMID: 30527195). | 30527195 | |
| ERBB2 Y772_A775dup | lung cancer | predicted - sensitive | Ado-trastuzumab emtansine | Preclinical - Pdx | Actionable | In a preclinical study, Kadcyla (ado-trastuzumab emtansine) treatment in a patient-derived xenograft (PDX) model of lung cancer harboring ERBB2 (HER2) Y772_A775dup resulted in a durable response and inhibition of tumor growth (PMID: 32213539). | 32213539 | |
| ERBB2 Y772_A775dup | lung cancer | sensitive | HER inhibitor (Pan) | Poziotinib | Preclinical | Actionable | In a preclinical study, Poziotinib (HM781-36B) induced regression of lung tumors in mouse models harboring ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA), with no signs of progression at 12 weeks (PMID: 29686424). | 29686424 |
| ERBB2 Y772_A775dup | lung adenocarcinoma | predicted - sensitive | Ado-trastuzumab emtansine | Case Reports/Case Series | Actionable | In a Phase II trial, Kadcyla (trastuzumab emtansine) treatment resulted in best overall responses of partial response (PR) in 44% (8/18) and stable disease in 39% (7/18), and median progression-free survival of 5 months in lung adenocarcinoma patients harboring ERBB2 (HER2) activating mutations, and a subset of patients harboring ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, E770delinsEAYVM) had a 60% (3/5) PR rate (PMID: 29989854; NCT02675829). | 29989854 | |
| ERBB2 Y772_A775dup | Her2-receptor negative breast cancer | predicted - sensitive | HER2 Inhibitor | Neratinib | Case Reports/Case Series | Actionable | In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in complete response in one patient, and stable disease in 2 patient with Erbb2 (Her2) receptor negative (non-amplified) breast cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 29420467; NCT01953926). | 29420467 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER2 Inhibitor | Tarloxotinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Tarloxotinib (TRLX) in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | no benefit | HER2 Inhibitor | Neratinib | Phase II | Actionable | In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in stable disease in 5 patients and progressive disease in 4 patients with non-small cell lung cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 29420467; NCT01953926). | 29420467 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | conflicting | HER2 Inhibitor | Pyrotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Pyrotinib inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) in culture (PMID: 30527195). | 30527195 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | conflicting | HER2 Inhibitor | Pyrotinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y722_A755dup were resistant to Pyrotinib in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | lung adenocarcinoma | no benefit | HER inhibitor (Pan) | Afatinib | Clinical Study - Cohort | Actionable | In a retrospective study, Gilotrif (afatinib) treatment resulted in an objective response rate (ORR) of 15.6% (5/32) and a disease control rate of 68.8% (22/32) in patients with lung adenocarcinoma harboring ERBB2 (HER2) mutations, ORR (0%, 0/14), DCR (35.7%, 5/14), and median progression-free survival (1.2 mo) were significantly lower in patients with Y772_A775dup than those with other exon 20 insertions (40%, 4/10; 100%, 10/10; 7.6 mo) or missense mutations (13%, 1/8; 75%, 6/8; 3.6 mo) (PMID: 32162827). | 32162827 |
| ERBB2 Y772_A775dup | lung adenocarcinoma | no benefit | HER inhibitor (Pan) | Afatinib | Case Reports/Case Series | Actionable | In a clinical study, a lung adenocarcinoma patient harboring ERBB2 Y772_A775dup (also referred to as A775_G776insYVMA and E740_A741insAYVM) achieved a partial response for 5 months following treatment with pulse Gilotrif (afatinib), however, a second patient harboring ERBB2 Y772_A775dup treated with pulse Gilotrif (afatinib) demonstrated progressive disease (PMID: 26964772). | 26964772 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | AZ5104 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to AZ5104 in culture (PMID: 30527195). | 30527195 | |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Erlotinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to Tarceva (erlotinib) in culture (PMID: 30527195). | 30527195 | |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER2 Inhibitor | Tucatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to Tukysa (tucatinib) in culture (PMID: 30527195). | 30527195 |
| ERBB2 Y772_A775dup | urinary bladder cancer | predicted - resistant | HER2 Inhibitor | Neratinib | Case Reports/Case Series | Actionable | In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.7 months in a patients with bladder cancer harboring ERBB2 (HER2) Y722_A775dup (PMID: 29420467; NCT01953926). | 29420467 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Tagrisso (osimertinib) in culture (PMID: 31588020). | 31588020 | |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to Tagrisso (osimertinib) in culture (PMID: 30527195). | 30527195 | |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Osimertinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM) demonstrated resistance to Tagrisso (osimertinib) treatment in culture (PMID: 29967253). | 29967253 | |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | conflicting | HER2 Inhibitor | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nerlynx (neratinib) inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as ERBB2 A775_G776insYVMA) in culture (PMID: 28363995). | 28363995 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | conflicting | HER2 Inhibitor | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Nerlynx (neratinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | conflicting | HER2 Inhibitor | Neratinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM) demonstrated partial sensitivity to Nerlynx (neratinib) treatment in culture (PMID: 29967253). | 29967253 |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, treatment with Gilotrif (afatinib) resulted in decreased cell viability of patient-derived non-small cell lung cancer organoids harboring ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM), and inhibited tumor growth and induced regression in patient-derived xenograft (PDX) models, but to a lesser degree than treatment with Pyrotinib (PMID: 30596880; NCT02535507). | 30596880 |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | sensitive | HER inhibitor (Pan) | Afatinib | Clinical Study | Actionable | In a retrospective analysis, Gilotrif (afatinib) treatment resulted in an objective response rate of 16% (5/31) in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (reported as (A775_G776insYVMA) (PMID: 30527195). | 30527195 |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | sensitive | HER inhibitor (Pan) | Ado-trastuzumab emtansine + Poziotinib | Preclinical - Pdx | Actionable | In a preclinical study, Poziotinib (HM781-36B) and Kadcyla (ado-trastuzumab emtansine) combination treatment resulted in sustained tumor regression in patient-derived xenograft models of non-small cell lung cancer harboring ERBB2 (HER2) Y772_A775dup (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER2 Inhibitor | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM) demonstrated resistance to Tykerb (lapatinib) treatment in culture (PMID: 29967253). | 29967253 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER2 Inhibitor | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) were resistant to Tykerb (lapatinib) in culture (PMID: 30527195). | 30527195 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER2 Inhibitor | Lapatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Tykerb (lapatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | no benefit | HER inhibitor (Pan) | Dacomitinib | Clinical Study | Actionable | In a retrospective analysis, Vizimpro (dacomitinib) treatment resulted in an objective response rate of 0% (0/13) in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (reported as (A775_G776insYVMA) (PMID: 30527195). | 30527195 |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | sensitive | HER2 Inhibitor | Pyrotinib | Case Reports/Case Series | Actionable | \In a Phase II trial, Pyrotinib treatment led to an objective response rate of 50% (5/10) and a progression-free survival of 4.1 mon., in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, E770delinsEAYVM), and reduced cell viability in patient-derived organoids, and inhibited tumor growth and induced regression in patient-derived xenograft (PDX) models (PMID: 30596880; NCT02535507). | 30596880 |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | sensitive | HER2 Inhibitor | Pyrotinib | Phase II | Actionable | In a Phase II trial, Pyrotinib treatment resulted in an objective response rate of 27.3% (12/44) in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (also reported as A775_G776insYVMA or M774_A775insAYVM) who had received prior platinum-based chemotherapy (PMID: 32614698; NCT02834936). | 32614698 |
| ERBB2 Y772_A775dup | lung cancer | sensitive | HER inhibitor (Pan) | Afatinib | Preclinical | Actionable | In a preclinical study, Gilotrif (afatinib) inhibited Erbb2 (Her2) phosphorylation and downstream signaling in bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) in culture (PMID: 26545934). | 26545934 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | conflicting | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Gilotrif (afatinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | conflicting | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM) demonstrated partial sensitivity to Gilotrif (afatinib) treatment in culture (PMID: 29967253). | 29967253 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | conflicting | HER inhibitor (Pan) | Afatinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) demonstrated decreased response to Gilotrif (afatinib) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195). | 30527195 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Trastuzumab | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM) demonstrated resistance to Herceptin (trastuzumab) treatment in culture (PMID: 29967253). | 29967253 | |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 | |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | sensitive | Ado-trastuzumab emtansine | Preclinical - Pdx | Actionable | In a preclinical study, treatment with Kadcyla (ado-trastuzumab emtansine) resulted in tumor growth inhibition and tumor regression of patient-derived xenograft (PDX) models harboring ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM), but to a lesser degree than treatment with Pyrotinib (PMID: 30596880; NCT02535507). | 30596880 | |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | sensitive | Ado-trastuzumab emtansine | Case Reports/Case Series | Actionable | In a Phase II trial, Kadcyla (ado-trastuzumab emtansine) treatment demonstrated limited efficacy in patients with relapsed non-small cell lung cancer harboring ERBB2 (HER2) mutations, resulting in a partial response in 20% (1/5) and stable disease in 60% (3/5) of patients harboring ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM) (PMID: 29313813). | 29313813 | |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER inhibitor (Pan) | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) demonstrated decreased response to Vizimpro (dacomitinib) compared to Poziotinib (HM781-36B) in culture (PMID: 30527195). | 30527195 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER inhibitor (Pan) | Dacomitinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Vizimpro (dacomitinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | breast cancer | sensitive | HER inhibitor (Pan) | Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Poziotinib (HM781-36B) inhibited viability of breast cancer cells expressing ERBB2 (HER2) Y772_A775dup in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | no benefit | Erlotinib | Clinical Study | Actionable | In a retrospective analysis, Tarceva (erlotinib) treatment resulted in an objective response rate of 0% (0/1) in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (reported as (A775_G776insYVMA) (PMID: 30527195). | 30527195 | |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | predicted - sensitive | HER inhibitor (Pan) | Poziotinib | Clinical Study | Actionable | In a retrospective analysis, Poziotinib (HM781-36B) treatment resulted in an objective response rate of 33% (1/3) in non-small cell lung cancer patients harboring ERBB2 (HER2) Y772_A775dup (reported as (A775_G776insYVMA) (PMID: 30527195). | 30527195 |
| ERBB2 Y772_A775dup | lung non-small cell carcinoma | predicted - sensitive | HER inhibitor (Pan) | Poziotinib | Phase II | Actionable | In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in a confirmed objective response rate of 42% (5/12) in patients with non-small cell lung cancer harboring ERBB2 (HER2) Y772_A775dup (n=9) or ERBB2 (HER2) G778_P780dup (n=3), with a median progression-free survival of 5.6 months (PMID: 31588020; NCT03066206). | 31588020 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | HER2 Inhibitor | Ibrutinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Imbruvica (ibrutinib) in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | lung cancer | no benefit | Gefitinib | Preclinical | Actionable | In a preclinical study, bronchial epithelial cells expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA) did not demonstrate sensitivity to Iressa (gefitinib) in culture (PMID: 26545934). | 26545934 | |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | predicted - sensitive | Ganetespib | Preclinical - Cell culture | Actionable | In a preclinical study, Ganetespib inhibited growth of transformed cells expressing ERBB2 (HER2) Y772_A775dup (reported as reported as A775_G776insYVMA) in culture (PMID: 30527195). | 30527195 | |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Poziotinib (HM781-36B) inhibited survival of transformed cells expressing ERBB2 (HER2) Y772_A775dup in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | sensitive | HER inhibitor (Pan) | Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, Poziotinib (HM781-36B) inhibited ERBB2 (HER2) phosphorylation and growth of a transformed cell line expressing ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) in culture (PMID: 29686424). | 29686424 |
| ERBB2 Y772_A775dup | breast cancer | sensitive | HER inhibitor (Pan) | Ado-trastuzumab emtansine + Poziotinib | Preclinical - Cell culture | Actionable | In a preclinical study, addition of Poziotinib (HM781-36B) enhanced growth inhibition by Kadcyla (ado-trastuzumab emtansine) treatment in breast cancer cells expressing ERBB2 (HER2) Y772_A775dup in culture (PMID: 31588020). | 31588020 |
| ERBB2 Y772_A775dup | lung adenocarcinoma | predicted - sensitive | HER inhibitor (Pan) | Poziotinib | Case Reports/Case Series | Actionable | In a Phase II trial, Poziotinib (HM781-36B) treatment resulted in one partial response, stable disease in one patient, and progressive disease in three patients with lung adenocarcinoma harboring ERBB2 (HER2) Y772_A775dup (reported as A775_G776insYVMA) (PMID: 30149884; NCT02979821). | 30149884 |
| ERBB2 Y772_A775dup | Advanced Solid Tumor | sensitive | JQ1 + Osimertinib | Preclinical | Actionable | In a preclinical study, transgenic mouse models expressing ERBB2 (HER2) Y772_A775dup (also referred to as A775_G776insYVMA, M774_A775insAYVM, E770_A771insAYVM, and E770delinsEAYVM) demonstrated greater tumor regression when treated with the combination of JQ1 and Tagrisso (osimertinib) compared to treatment with either agent alone, which resulted in little to no regression (PMID: 29298799). | 29298799 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03066206 | Phase II | Poziotinib | Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC | Recruiting | USA | 0 |
| NCT02673398 | Phase II | Neratinib | Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer | Active, not recruiting | USA | 0 |
| NCT02675829 | Phase II | Ado-trastuzumab emtansine | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | Recruiting | USA | 0 |